Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 6, 2014-- Lorcaserin Evaluated for Effect on the NASH Clinical Score: A Retrospective Analysis of Three Phase 3 Studies --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the...
-
Nov 3, 2014-- Trial Met Primary Efficacy Endpoint with Statistical Significance After 12 Weeks of Treatment --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking...
-
Oct 31, 2014-- Results of Investigational Study of Coadministration of Lorcaserin and Phentermine Accepted as Late Breaking Poster --
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the...
-
Oct 28, 2014-- Trial Met Primary Safety Objective After 12 Weeks of Treatment -- -- Data to be Presented at The Obesity Society 2014 Annual Meeting During ObesityWeekSM --
WOODCLIFF LAKE, NJ and SAN DIEGO, CA, October 28, 2014 – Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of...
- Oct 20, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor...
- Oct 14, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's sNDA for rufinamide and granted it priority review designation as an adjunctive treatment of...
-
Oct 13, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
- Oct 10, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ® (lorcaserin HCl) was...
- Oct 1, 2014Findings suggest need for improved education efforts within epilepsy community and beyond to address misperceptions about the disease
Results from a national survey conducted by Eisai Inc., in partnership with the Epilepsy Foundation, found that the vast majority (95%) of epilepsy patients and caregivers believe the public is...
-
Sep 10, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
